
InflaRx N.V (IFRX)
Last updated: 2026-10-21 16:19:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
InflaRx N.V (IFRX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.60, with a market capitalization of $213.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.80 to $2.95. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$213.68M | |
$1.55 | |
$53.10 | |
$0.71 | |
$1.54 | |
448.56K | |
792.09K | |
-- | |
$2.95 | |
$0.80 | |
-- | |
-- |
InflaRx N.V (IFRX) Stock Price Today
InflaRx N.V (IFRX) is currently trading at $1.60 as of 2026-10-21 16:17:00, up 3.57% ($0.05) from the previous close of $1.54
During today's regular trading session, IFRX has traded between $0.71 and $53.10, with a trading volume of 448.56K shares. The current price is near the lower end of today's range.
InflaRx N.V (IFRX) 7-Day Stock Price Change
Over the past seven days, InflaRx N.V (IFRX) moved from $1.59 to $1.60, representing a gain of 0.31% ($0.00).
The stock traded between $1.29 and $1.64 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 1.01 million shares, up versus the previous seven-day period, indicating higher trading activity.
IFRX 52-Week Price Position
Position in Range: 37.0%
IFRX is currently trading at $1.60, placing it 37.0% of the way from its 52-week low of $0.80 to its 52-week high of $2.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is InflaRx N.V (IFRX)?
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
InflaRx N.V Information
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
How to Buy InflaRx N.V (IFRX) Stock on MEXC
Eligible investors can buy real shares of InflaRx N.V (IFRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is InflaRx N.V (IFRX) stock price today?
2.Is IFRX stock going up or down today?
3.What is IFRX pre-market price?
4.What is IFRX after-hours price?
5.Is IFRX stock trading now?
6.Where does IFRX sit relative to its 52-week high and low?
7.What sector is InflaRx N.V in?
8.What is InflaRx N.V's market capitalization and where is it listed?
9.How is IFRX valued in terms of P/E ratio and EPS?
10.Does InflaRx N.V pay a dividend?
Explore More US Stocks
Search Stocks
IFRX Stock Calculator
Estimate the value between IFRX shares and USD.
IFRX Shares to USD
1.00 IFRX shares = 1.595 USD
Calculations are estimates based on the latest available price and are for reference only.


